An interventional study of Carboxymethylcellulose and Glycerin based artificial tear and Carboxymethylcellulose in Dry Eye Syndrome, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-15.
Sponsored by Allergan (part of AbbVie) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Dry Eye Syndromes by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · AbbVie.
Among the 48 studies in Dry Eye Syndromes by AbbVie, this one is the 3rd largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2007, is one of 11 with no phase, and was the 3rd registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →1 of the 48 studies in Dry Eye Syndromes by AbbVie is open now, in 3 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, France, Netherlands
Ages 18–75
By country, each count listing its studies:
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 13 · Phase 4 9
First in 2001; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 316 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 80 across the 40 interventional studies, 128 across the 8 observational. Of the 47 that completed or were terminated, 40 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 48 studies in Dry Eye Syndromes by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The efficacy, safety and acceptability of a new artificial tear in subjects with dry eye will be compared to a currently-available artificial tear
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Carboxymethylcellulose and Glycerin based artificial tear
Drug: Carboxymethylcellulose and Glycerin based artificial tear
Carboxymethylcellulose
Drug: Carboxymethylcellulose
1 to 2 drops into each eye as needed but at least twice daily
1 to 2 drops into each eye as needed but at least twice daily
Also known as: Refresh Plus
Change From Baseline at Day 30 in Ocular Surface Disease Index© Questionnaire Score
Ocular Surface Disease Index© Questionnaire Score is measured on 12 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity)
Time frame: Change from baseline at Day 30
Change From Baseline at Day 30 in Schirmer Test, With Anesthesia
Schirmer Test measures the rate of the secretion of tears
Time frame: Change from baseline at Day 30
Change From Baseline at Day 30 in Tear Break-Up Time, With Fluorescein
Measures the stability of tear film. The average of 3 measures.
Time frame: Change from baseline at Day 30
Patient Acceptability Score (Dryness) at Day 30
Dryness Severity Visual Analog Scale is measured on a 0-100 point scale (0 = could not be worse, 100 = none at all).
Time frame: Day 30
Patient Acceptability Score (Vision) at Day 30
Vision Quality Visual Analog Scale is measured on a 0-100 point scale (0 = very poor, has never been worse, 100 = excellent, has never been better).
Time frame: Day 30
Change From Baseline at Day 30 in Ocular Surface (Corneal) Staining With Fluorescein
Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-25 (0= no staining, 25 = most severe staining)
Time frame: Change from baseline at Day 30
Change From Baseline at Day 30 in Ocular Surface (Conjunctival) Staining With Fluorescein
Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-30 (0=no staining, 30=most severe staining)
Time frame: Change from baseline at Day 30
Change From Baseline at Day 30 in Subjective Evaluation of Symptom of Dryness Score
Measures dry eye severity on a scale of 0-4 (0 = none, 4 = severe)
Time frame: Change from baseline at Day 30
| Milestone | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Started | 157 | 159 |
| Completed | 152 | 154 |
| Not completed | 5 | 5 |
Ocular Surface Disease Index© Questionnaire Score is measured on 12 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity)
| Units on a scale | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Day 1 (Baseline) | 44 ± 18.1 | 45.2 ± 18.3 |
| Day 7 | -12.6 ± 14.9 | -13.6 ± 17.8 |
| Day 30 | -16.3 ± 16.4 | -16.6 ± 20.3 |
Schirmer Test measures the rate of the secretion of tears
| mm/5min | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Day 1 (Baseline) | 9.2 ± 7.2 | 8.6 ± 6.8 |
| Day 7 | 1.2 ± 5.1 | 1.2 ± 5.6 |
| Day 30 | 1.7 ± 6.9 | 1.8 ± 7.3 |
Measures the stability of tear film. The average of 3 measures.
| seconds | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Day 1 (Baseline) | 4.3 ± 2.1 | 4.3 ± 2.0 |
| Day 7 | 0.9 ± 2.3 | 0.9 ± 2.1 |
| Day 30 | 1.1 ± 2.7 | 0.9 ± 2.4 |
Dryness Severity Visual Analog Scale is measured on a 0-100 point scale (0 = could not be worse, 100 = none at all).
| Units on scale | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Day 1 (Baseline) | 47.4 ± 22.8 | 44.6 ± 20.5 |
| Day 7 | 60.7 ± 21.1 | 57.7 ± 22.5 |
| Day 30 | 63.3 ± 22.7 | 63.8 ± 22.8 |
Vision Quality Visual Analog Scale is measured on a 0-100 point scale (0 = very poor, has never been worse, 100 = excellent, has never been better).
| Units on a scale | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Day 1 (Baseline) | 56.8 ± 22.4 | 54.2 ± 21.6 |
| Day 7 | 65.3 ± 17.8 | 62.6 ± 19.6 |
| Day 30 | 65.4 ± 20.1 | 66.4 ± 19.4 |
Vision subscale of the Ocular Surface Disease Index Questionnaire© is measured on 6 domains; a 5-point scale (0-4) for each domain. Sum of the domain scores is normalized to a severity scale of 0-100 (0 = no symptoms, 100 = maximum severity)
| Units on a scale | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Day 1 (Baseline) | 37.6 ± 21.5 | 41.6 ± 21.6 |
| Day 7 | 24.8 ± 20.0 | 26.9 ± 20.2 |
| Day 30 | 22.8 ± 20.4 | 25.6 ± 22.4 |
Central staining score is based on modified Oxford Scheme measured on a scale of 0-5 (0= no staining, 5= most severe staining)
| Units on a scale | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Day 1 (Baseline) | 0.7 ± 0.8 | 0.8 ± 0.8 |
| Day 7 | 0.5 ± 0.7 | 0.5 ± 0.7 |
| Day 30 | 0.4 ± 0.6 | 0.4 ± 0.7 |
Sum of corneal staining over 5 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-25 (0= no staining, 25 = most severe staining)
| Units on a scale | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Day 1 (Baseline) | 4.0 ± 3.3 | 4.4 ± 3.4 |
| Day 7 | -1.2 ± 2.3 | -0.9 ± 2.4 |
| Day 30 | -1.3 ± 2.4 | -1.5 ± 2.5 |
Sum of conjunctival staining over 6 zones; each zone was measured on a modified Oxford Scheme of 0-5 (0=no staining, 5=most severe staining), with total score from 0-30 (0=no staining, 30=most severe staining)
| Units on a scale | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Day 1 (Baseline) | 4.9 ± 4.4 | 5.1 ± 5.0 |
| Day 7 | -1.1 ± 3.1 | -1.0 ± 3.2 |
| Day 30 | -1.7 ± 3.3 | -1.5 ± 2.8 |
Measures dry eye severity on a scale of 0-4 (0 = none, 4 = severe)
| Units on a scale | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Day 1 (Baseline) | 2.8 ± 0.7 | 2.8 ± 0.8 |
| Day 7 | -0.5 ± 0.8 | -0.5 ± 0.8 |
| Day 30 | -0.7 ± 1.0 | -0.7 ± 0.9 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carboxymethylcellulose and Glycerin Based Artificial Tear | — | 1/157 (0.6%) | 0/157 (0%) |
| Carboxymethylcellulose Based Artificial Tear | — | 1/159 (0.6%) | 0/159 (0%) |
| Event | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear |
|---|---|---|
| Transient Ischaemic AttackNervous system disorders | 1/157 | 0/159 |
| MenorrhagiaReproductive system and breast disorders | 0/157 | 1/159 |
| Age, Customized(participants) | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear | Total |
|---|---|---|---|
| <40 years | 18 | 15 | 33 |
| >=40 years | 139 | 144 | 283 |
| Sex: Female, Male(Participants) | Carboxymethylcellulose and Glycerin Based Artificial Tear | Carboxymethylcellulose Based Artificial Tear | Total |
|---|---|---|---|
| Female | 120 | 125 | 245 |
| Male | 37 | 34 | 71 |
The record gives a start of Oct 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.